Human medicines European public assessment report (EPAR): Vepacel, Prepandemic influenza vaccine (H5N1) (whole virion, inactivated,prepared in cell culture), Influenza, Human,Immunization,Disease Outbreaks, Date of authorisation: 17/02/2012, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Pandemic Influenza Vaccine H5N1 Baxter AG, pandemic influenza vaccine (H5N1) (whole virion, inactivated, prepared in cell culture), Influenza, Human,Immunization,Disease Outbreaks, Date of authorisation: 12/12/2018, Revision: 6, Status: Authorised

Case Medical Research ◽

10.31525/cmr-91357e ◽

2019 ◽

Author(s):

Keyword(s):

Cell Culture ◽

Influenza Vaccine ◽

Pandemic Influenza ◽

Disease Outbreaks ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Vepacel, Prepandemic influenza vaccine (H5N1) (whole virion, inactivated,prepared in cell culture), Influenza, Human,Immunization,Disease Outbreaks, Date of authorisation: 17/02/2012, Revision: 9, Status: Authorised

Case Medical Research ◽

10.31525/cmr-95e8e9 ◽

2019 ◽

Author(s):

Keyword(s):

Cell Culture ◽

Influenza Vaccine ◽

Disease Outbreaks ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Pandemic Influenza Vaccine H5N1 Baxter AG, pandemic influenza vaccine (H5N1) (whole virion, inactivated, prepared in cell culture), Influenza, Human,Immunization,Disease Outbreaks, Date of authorisation: 12/12/2018, Revision: 6, Status: Authorised

Case Medical Research ◽

10.31525/cmr-908f22 ◽

2019 ◽

Author(s):

Keyword(s):

Cell Culture ◽

Influenza Vaccine ◽

Pandemic Influenza ◽

Disease Outbreaks ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Aflunov, prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), Influenza, Human,Immunization,Disease Outbreaks, Date of authorisation: 28/11/2010, Revision: 11, Status: Authorised

Case Medical Research ◽

10.31525/cmr-175590d ◽

2019 ◽

Author(s):

Keyword(s):

Influenza Vaccine ◽

Surface Antigen ◽

Disease Outbreaks ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Foclivia, pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), Influenza, Human,Immunization,Disease Outbreaks, Date of authorisation: 18/10/2009, Revision: 8, Status: Authorised

Case Medical Research ◽

10.31525/cmr-913586 ◽

2019 ◽

Author(s):

Keyword(s):

Influenza Vaccine ◽

Surface Antigen ◽

Pandemic Influenza ◽

Disease Outbreaks ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals), pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted), Influenza, Human,Immunization,Disease Outbreaks, Date of authorisation: 10/10/2009, Revision: 9, Status: Authorised

Case Medical Research ◽

10.31525/cmr-5871ee ◽

2018 ◽

Author(s):

Keyword(s):

Influenza Vaccine ◽

Pandemic Influenza ◽

Disease Outbreaks ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Foclivia, pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), Influenza, Human,Immunization,Disease Outbreaks, Date of authorisation: 18/10/2009, Revision: 6, Status: Authorised

Case Medical Research ◽

10.31525/cmr-908f29 ◽

2019 ◽

Author(s):

Keyword(s):

Influenza Vaccine ◽

Surface Antigen ◽

Pandemic Influenza ◽

Disease Outbreaks ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Prepandrix, prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted), Influenza, Human,Immunization,Disease Outbreaks, Date of authorisation: 14/05/2008, Revision: 13, Status: Authorised

Case Medical Research ◽

10.31525/cmr-189d3a4 ◽

2019 ◽

Author(s):

Keyword(s):

Influenza Vaccine ◽

Disease Outbreaks ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals), pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted), Influenza, Human,Immunization,Disease Outbreaks, Date of authorisation: 10/10/2009, Revision: 9, Status: Authorised

Case Medical Research ◽

10.31525/cmr-3c3d80 ◽

2018 ◽

Author(s):

Keyword(s):

Influenza Vaccine ◽

Pandemic Influenza ◽

Disease Outbreaks ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Flucelvax Tetra, influenza vaccine surface antigen inactivated prepared in cell cultures, Influenza, Human, Date of authorisation: 12/12/2018, Revision: 3, Status: Authorised

Case Medical Research ◽

10.31525/cmr-1569d0a ◽

2019 ◽

Author(s):

Keyword(s):

Influenza Vaccine ◽

Cell Cultures ◽

Surface Antigen ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text